512,000 adults in China have been enrolled in one of the world’s largest studies of chronic disease, with their blood, lifestyle, and health tracked for over a decade. This matters because most large-scale studies of this kind have focused on Western populations. Genetic and environmental causes of disease can differ dramatically between populations, so findings from one group may not apply to another. Without data from China—home to one-fifth of the world’s population—scientists have been working with an incomplete picture of what drives stroke, heart disease, diabetes, and cancer globally. If this research succeeds, it will fill that gap. By comparing blood biomarkers, genetic profiles, and lifestyle data from people who developed a disease against those who did not, researchers can identify new risk factors and protective factors. This could lead to more accurate risk prediction tools and new treatment targets that work across diverse populations. The findings will also help refine prevention strategies—for example, dietary or environmental interventions—that are relevant to people in China and beyond. The study is fundamentally about understanding causation in human disease. While it has clear practical goals, its core value lies in building a detailed, population-specific evidence base that other researchers will mine for decades.
View original technical description
Chronic diseases, such as stroke, heart disease, diabetes and cancer, are the leading causes of disability and death worldwide. Understanding what causes these diseases in different populations can lead to improvements in disease prevention, risk prediction and development of new treatments. One way of identifying causes of disease is through blood-based “prospective cohort” studies, in which large numbers of apparently healthy individuals from the general population are interviewed and measured, and have blood collected and stored for future tests of genetic and non-genetic biomarkers. The health status of the study participants is then monitored “prospectively” to see who develops what disease. When sufficiently large numbers of people have developed a particular disease (“cases”), their blood and other characteristics are compared with those from “controls” who have not developed the disease. We have established one of the world’s largest studies of this kind, involving 512,000 adults in China during 2004-08. After 10-year follow-up, large numbers of disease outcomes have been accumulated, which, together with other lifestyle, environment, genetic and blood biomarker data, will enable scientists to make important discoveries about genetic and non-genetic causes of many diseases. The study findings will help improve disease prevention, prediction and treatment, benefiting populations worldwide.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know